Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2109241 Target Snapshot

Glutamate receptor ionotropic kainate · PROTEIN COMPLEX GROUP · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
61Compounds
23Assays
0Approved Drugs
57.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-15

Glutamate receptor ionotropic kainate shows approved-linked disease relevance led by epilepsy. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P39086. Start with epilepsy, then reuse UniProt P39086 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with epilepsy, then reuse UniProt P39086 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-15 2 linked drugs
Open source guide
Disease program
epilepsy

Glutamate receptor ionotropic kainate shows approved-linked disease relevance led by epilepsy. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with epilepsy because it currently carries approved-linked support. Linked drugs include SELURAMPANEL, TOPIRAMATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Glutamate receptor ionotropic kainate as ChEMBL target CHEMBL2109241, mapped to UniProt P39086. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Glutamate receptor ionotropic kainate
PROTEIN COMPLEX GROUP · Homo sapiens
As of 2026-09-15
ChEMBL target ID
CHEMBL2109241
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-15
www.ebi.ac.uk
UniProt accession
P39086
Glutamate receptor ionotropic, kainate 1
UniProt accession via ChEMBL component mapping As of 2026-09-15
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-15
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Glutamate receptor ionotropic kainate is the right protein anchor across sources, using UniProt P39086 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why epilepsy is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameGlutamate receptor ionotropic kainate
Target TypePROTEIN COMPLEX GROUP
OrganismHomo sapiens
UniProtP39086
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelGlutamate receptor ionotropic, kainate 1
UniProt AccessionP39086
Component TypeProtein
Sequence Length918 aa

Glutamate receptor ionotropic, kainate 1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Glutamate receptor ionotropic kainate, mapped to UniProt P39086. ChEMBL maps the protein component as Glutamate receptor ionotropic, kainate 1. Sequence length is 918 aa.

Mapped IDP39086
Review nameGlutamate receptor ionotropic kainate
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Glutamate receptor ionotropic kainate shows approved-linked disease relevance led by epilepsy. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
epilepsy
2 linked drugs · 2 direct · 2 efficacy
Linked drugSELURAMPANEL
Linked drugTOPIRAMATE
Approved-linked Approved
migraine disorder
2 linked drugs · 2 direct · 2 efficacy
Linked drugSELURAMPANEL
Linked drugTOPIRAMATE
Approved-linked Approved
Seizure
2 linked drugs · 2 direct · 2 efficacy
Linked drugSELURAMPANEL
Linked drugTOPIRAMATE
Approved-linked Approved
Lennox-Gastaut syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugTOPIRAMATE
Late clinical Phase III
alcohol abuse
1 linked drug · 1 direct · 1 efficacy
Linked drugTOPIRAMATE
Late clinical Phase III
alcohol dependence
1 linked drug · 1 direct · 1 efficacy
Linked drugTOPIRAMATE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with epilepsy because it currently carries approved-linked support. Linked drugs include SELURAMPANEL, TOPIRAMATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseepilepsy
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Phase II
Assay Mix

Activity Type Distribution

IC5026.0
KI31.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL13076 7.16 Ki 70.0 Preclinical
CHEMBL275040 7.11 IC50 77.0 Clinical
CHEMBL12696 6.96 Ki 110.0 Preclinical
CHEMBL273675 6.96 Ki 110.0 Preclinical
CHEMBL268284 6.39 Ki 410.0 Preclinical
CHEMBL84142 6.16 Ki 700.0 Preclinical
CHEMBL82375 5.92 Ki 1200.0 Preclinical
CHEMBL12448 5.82 Ki 1500.0 Preclinical
CHEMBL12989 5.78 Ki 1670.0 Preclinical
CHEMBL12761 5.58 Ki 2600.0 Preclinical
Distribution

pChEMBL Value Distribution

14
5.0
9
5.5
2
6.0
2
6.5
2
7.0
0
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

23
Total Assays
37
Tested Compounds
1
Assay Types
Binding — 23 assays, 37 compounds
BAO Format Assays Compounds Avg pChEMBL
protein complex format 23 37 5.4

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine